Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02296242 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes
A Phase 1 study, sponsored by BioMed Valley Discoveries.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT02296242 is a Phase 1 study that has completed, run by BioMed Valley Discoveries. The registered enrollment target is 53 participants.
The verdict
NCT02296242, a Phase 1 study, has completed, sponsored by BioMed Valley Discoveries.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
This study is being performed to assess the safety, tolerability, and preliminary clinical effects of BVD-523 given orally, twice daily for 21-day cycles, in patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS).
Interventions
- DRUG BVD-523
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2014-11 |
| Est. Completion | 2017-06-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02296242
The ClinicalTrials.gov registry entry for NCT02296242 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMed Valley Discoveries, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BVD-523 is the first listed.
NCT02296242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02296242 about?
NCT02296242 is a clinical study titled "Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes". This study is being performed to assess the safety, tolerability, and preliminary clinical effects of BVD-523 given orally, twice daily for 21-day cycles, in patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS).
What is the current status of trial NCT02296242?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2014-11. Estimated completion is 2017-06-15.
What interventions are being tested in trial NCT02296242?
The interventions under investigation include: BVD-523 (DRUG).
Who is sponsoring clinical trial NCT02296242?
This trial is sponsored by BioMed Valley Discoveries, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.